ALCLS.PA
Cellectis SA
Price:  
2.81 
EUR
Volume:  
119,612.00
France | Biotechnology
Valuation
Overview
Financials
Forecast
Compare
Historical Price
SolvencyDividends
Transactions
People

ALCLS.PA EV/EBITDA

-200.2%
Upside

As of 2026-03-29, the EV/EBITDA ratio of Cellectis SA (ALCLS.PA) is -12.75. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. ALCLS.PA's latest enterprise value is 244.19 mil EUR. ALCLS.PA's TTM EBITDA according to its financial statements is -19.15 mil EUR. Dividing these 2 quantities gives us the above ALCLS.PA EV/EBITDA ratio.

Note: valuation result may not be accurate due to the company's negative EBITDA.

Range Selected
Trailing P/E multiples 8.0x - 11.0x 9.7x
Forward P/E multiples 8.1x - 10.5x 9.7x
Fair Price (2.46) - (3.00) (2.82)
Upside -187.4% - -206.6% -200.2%
2.81 EUR
Stock Price
(2.82) EUR
Fair Price

ALCLS.PA EV/EBITDA - Historical EV/EBITDA Data

Date EV/EBITDA
2026-03-23 -15.57
2026-03-20 -15.20
2026-03-19 -15.37
2026-03-18 -15.85
2026-03-17 -16.02
2026-03-16 -15.93
2026-03-13 -16.15
2026-03-12 -16.32
2026-03-11 -17.10
2026-03-10 -17.47
2026-03-09 -16.63
2026-03-06 -16.19
2026-03-05 -16.84
2026-03-04 -16.84
2026-03-03 -16.41
2026-03-02 -17.23
2026-02-27 -17.43
2026-02-26 -17.71
2026-02-25 -18.23
2026-02-24 -17.45
2026-02-23 -17.43
2026-02-20 -17.41
2026-02-19 -17.23
2026-02-18 -17.62
2026-02-17 -16.78
2026-02-16 -16.52
2026-02-13 -16.82
2026-02-12 -15.93
2026-02-11 -16.13
2026-02-10 -17.13
2026-02-09 -16.32
2026-02-06 -15.96
2026-02-05 -16.17
2026-02-04 -16.04
2026-02-03 -16.37
2026-02-02 -16.74
2026-01-30 -16.58
2026-01-29 -16.65
2026-01-28 -17.32
2026-01-27 -17.91
2026-01-26 -17.62
2026-01-23 -18.69
2026-01-22 -18.32
2026-01-21 -17.52
2026-01-20 -17.65
2026-01-19 -17.95
2026-01-16 -17.62
2026-01-15 -18.01
2026-01-14 -17.84
2026-01-13 -18.14